Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Rhea-AI Summary

Aptevo Therapeutics (NASDAQ:APVO) reported Q3 2024 financial results and clinical progress. The company initiated the mipletamig Phase 1b/2 'RAINIER' trial for frontline AML treatment and presented positive interim data for ALG.APV-527 in solid tumors, showing 60% of evaluable patients achieving stable disease. Financial results showed cash position of $7.8 million, reduced R&D expenses to $3.1 million (down from $3.9 million), and decreased G&A expenses to $2.1 million (down from $2.7 million). The company reported a net loss of $5.1 million ($0.48 per share) and raised $5.75 million through financings during the quarter.

Positive

• Raised $5.75 million through financings in Q3
• 60% of evaluable patients achieved stable disease in ALG.APV-527 trial
• Reduced R&D expenses by $0.8 million year-over-year
• Decreased G&A expenses by $0.6 million year-over-year

Negative

• Net loss of $5.1 million in Q3 2024
• Cash position decreased to $7.8 million from $16.9 million at end of 2023
• Accumulated deficit increased to $241.3 million

Insights

Financial Analyst

The Q3 results reveal concerning financial metrics. Cash position declined to $7.8 million from $16.9 million at year-end 2023, despite raising $5.75 million in the quarter. The quarterly net loss of $5.1 million suggests a cash runway of approximately 4-5 months at current burn rates. While R&D and G&A expenses decreased by $0.8 million and $0.6 million respectively year-over-year, the company's financial position remains precarious given its market cap of just $3.6 million. Additional financing will likely be needed in early 2025, risking significant dilution for current shareholders.

Medical Research Analyst

The clinical progress shows promise despite financial constraints. The RAINIER trial advancement for mipletamig in frontline AML and ALG.APV-527's 60% stable disease rate in solid tumors demonstrate potential therapeutic value. The durability of response in breast cancer patients (>11 months) and clean safety profile are particularly encouraging. However, while stable disease is positive, the absence of partial or complete responses in the solid tumor program warrants cautious interpretation. The combination strategy with venetoclax in AML appears strategically sound given existing treatment paradigms.

Company Achieves Milestones in Both Clinical Programs

Initiates Mipletamig Phase 1b/2 Clinical Trial, "RAINIER," in Frontline Acute Myeloid Leukemia, Informed by Positive Dose Escalation Trial Results

Presented Interim Data from ALG.APV-527 Phase 1 Trial in Multiple Solid Tumors at the European Society for Medical Oncology Congress

Additional Favorable Data to be Presented at the Society for Immunotherapy of Cancer Conference on November 9^th

Raises $5.75 Million in the Quarter

SEATTLE, WA / ACCESSWIRE / November 7, 2024/ Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the quarter ending September 30, 2024 and provided a business update.

Business Highlights
Aptevo met multiple clinical milestones in the third quarter, including:

• Based on positive safety, tolerability efficacy and durability data in its completed dose escalation trial, Aptevo Initiated the mipletamig Phase 1b/2 dose optimization trial, "RAINIER," as part of its ongoing program to evaluate the compound in combination with standard of care venetoclax + azacitidine in frontline patients with acute myeloid leukemia (AML). RAINIER will be conducted in two parts. First, a Phase 1b frontline AML dose optimization study followed by a Phase 2 study

• Presented positive interim data from their Phase 1 trial evaluating ALG.APV-527 as monotherapy for the treatment of solid tumors likely to express the tumor antigen 5T4 at the European Society of Medical Oncology (ESMO) Congress in September. Additional positive trial data will be presented at the Society for Immunotherapy of Cancer conference on November 9^th.

• Highlights from the ESMO presentation include:

  • Clinical Activity/Efficacy: To date,nine of 15 efficacy evaluable patients (60%) have a best overall response of stable disease (SD). The longest SD duration was in a breast cancer patient who entered the study with progressive disease, achieved stable disease and remained on study for >11 months. This patient successfully transitioned to a higher dose level twice.

  • Safety and Tolerability: ALG.APV-527 demonstrated a well-tolerated safety profile across all dose-level cohorts dosed to date.

  • Evidence of biological activity: ALG.APV-527 could be measured in all patients with serum concentration of ALG.APV-527 consistent with the administered dose and preclinical predictions. Biomarker analyses confirm biological activity of ALG.APV-527

• Closed two financings for total proceeds of $5.75 million during the quarter

"Aptevo achieved significant clinical progress in both programs this quarter, marking important progress toward our mission and goals. We were thrilled to initiate the next phase of our mipletamig development program-a robust Phase 1b/2 trial for frontline AML patients, combining mipletamig with the established standard of care, venetoclax and azacitidine. This trial structure is informed by the encouraging results from our dose expansion trial, reinforcing our belief in mipletamig's transformative potential for AML patients," stated Marvin White, President and CEO of Aptevo. "We also released positive interim data on our solid tumor drug, ALG.APV-527, at the European Society of Medical Oncology conference in September that further underscores the impact of our innovation. In early clinical evaluation, our solid tumor targeting bispecific demonstrated safety, tolerability, and compelling activity, with 60% of evaluable patients achieving stable disease in monotherapy across challenging tumor types, including breast and colon cancer. The progress we're witnessing, combined with nearly $6 million in capital secured in the quarter, sets a promising stage for the fourth quarter and lays the groundwork for continued successes into 2025."

3Q Summary Financial Results

Cash Position: Aptevo had cash and cash equivalents totaling $7.8 million as of September 30, 2024.

Research and Development Expenses: Research and development expenses decreased by $0.8 million, from $3.9 million for the three months ended September 30, 2023, to $3.1 million for the three months ended September 30, 2024. The decrease was primarily due to lower spending on preclinical projects and employee costs.

General and Administrative Expenses: General and administrative expenses decreased by $0.6 million, from $2.7 million for the three months ended September 30, 2023, to $2.1 million for the three months ended September 30, 2024. The decrease is primarily due to lower employee and consulting costs.

Other Income (Expense), Net:
Other Income (Expense) from Continuing Operations, Net consists of other income, net of $0.1 million and $0.2 million for the three months ended September 30, 2024, and 2023, respectively. The change in other income, net is primarily due to the decrease of interest income from our money market accounts.

Net Income (Loss): Aptevo had a net loss of $5.1 million or $0.48 per share for the three months ended September 30, 2024, compared to a net loss of $6.3 million or $22.16 per share for the corresponding period in 2023.

Aptevo Therapeutics Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts, unaudited)

		September 30, 2024				December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents		$	7,753			$	16,904
Prepaid expenses			1,635				1,473
Other current assets			624				689
Total current assets			10,012				19,066
Property and equipment, net			614				895
Operating lease right-of-use asset			4,520				4,881
Total assets		$	15,146			$	24,842
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and other accrued liabilities		$	3,532			$	3,984
Accrued compensation			922				2,098
Other current liabilities			1,428				1,142
Total current liabilities			5,882				7,224
Other long-term liabilities			14				-
Operating lease liability			4,830				5,397
Total liabilities			10,726				12,621
Stockholders' equity:
Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding			-				-
Common stock: $0.001 par value; 500,000,000 shares authorized; 17,050,536 and 442,458 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively			82				61
Additional paid-in capital			245,603				235,607
Accumulated deficit			(241,265	)			(223,447	)
Total stockholders' equity			4,420				12,221
Total liabilities and stockholders' equity		$	15,146			$	24,842

Aptevo Therapeutics Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share amounts, unaudited)

		For the Three Months Ended September 30,								For the Nine Months Ended September 30,
		2024				2023				2024				2023
Operating expenses:
Research and development		$	(3,103	)		$	(3,887	)			(10,498	)			(13,516	)
General and administrative			(2,110	)			(2,674	)			(7,722	)			(8,978	)
Loss from operations			(5,213	)			(6,561	)			(18,220	)			(22,494	)
Other income:
Other income from continuing operations, net			112				227				402				390
Gain related to sale of non-financial asset			-				-				-				9,650
Net loss from continuing operations		$	(5,101	)		$	(6,334	)		$	(17,818	)		$	(12,454	)
Discontinued operations:
Income from discontinued operations		$	-			$	-			$	-			$	946
Net loss		$	(5,101	)		$	(6,334	)		$	(17,818	)		$	(11,508	)
Basic and diluted net loss per share from continuing operations:
Basic		$	(0.48	)		$	(22.16	)		$	(5.01	)		$	(60.84	)
Diluted		$	(0.48	)		$	(22.16	)		$	(5.01	)		$	(60.84	)
Basic and diluted net loss per share:
Basic		$	(0.48	)		$	(22.16	)		$	(5.01	)		$	(56.22	)
Diluted		$	(0.48	)		$	(22.16	)		$	(5.01	)		$	(56.22	)
Shares used in calculation:
Basic			10,548,470				285,886				3,554,796				204,694
Diluted			10,548,470				285,886				3,554,796				204,694

About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for the treatment of cancer. Aptevo is seeking to improve treatment outcomes for cancer patients. For more information, please visit www.aptevotherapeutics.com.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy, safety, tolerability and durability of its therapeutic candidates and potential use of any such candidates, including in combination with other drugs, as therapeutics for treatment of disease, its expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platforms, statements related to the progress of Aptevo's clinical programs, including statements related to anticipated clinical and regulatory milestones, whether further study of mipletamig in a Phase 1b dose optimization trial focusing on multiple doses of mipletamig in combination with venetoclax + azacitidine on a targeted patient population will continue to show clinical benefit, whether Aptevo's final trial results will vary from its earlier assessment, whether further study of ALG.APV-527 across multiple tumor types will continue to show clinical benefit, whether higher dose ranges for ALG.APV-527 will result in increased signs of clinical activity, whether biomarker analyses will continue to confirm biological activity of ALG.APV-527, the possibility and timing of future preliminary or interim data readouts for ALG.APV-527, whether Aptevo's final trial results will vary from its preliminary or interim assessments, statements related to the progress of and enthusiasm for Aptevo's clinical programs, statements related to Aptevo's cash position and balance sheet, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "continue to," "believes," "knows," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.

There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; and changes in regulatory, social, macroeconomic and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the results of preliminary or interim data and preclinical studies being predictive of the results of later-stage clinical trials, initiation, enrollment and maintenance of patients, and the completion of clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of Aptevo's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine, war between Israel and Hamas, and macroeconomic conditions such as economic uncertainty, rising inflation and interest rates, continued market volatility and decreased consumer confidence and uncertainty in the impact of the results of the United States presidential election and congressional election. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.

CONTACT:
Miriam Weber Miller
Head, Investor Relations & Corporate Communications
Aptevo Therapeutics
Email: IR@apvo.com or Millerm@apvo.com
Phone: 206-859-6628

SOURCE: Aptevo Therapeutics

View the original press release on accesswire.com

FAQ

What were Aptevo Therapeutics (APVO) Q3 2024 financial results?

Aptevo reported a net loss of $5.1 million ($0.48 per share), with cash position of $7.8 million, R&D expenses of $3.1 million, and G&A expenses of $2.1 million.

What clinical progress did APVO report in Q3 2024?

APVO initiated the mipletamig Phase 1b/2 'RAINIER' trial for frontline AML and presented positive interim data for ALG.APV-527, showing 60% of patients achieving stable disease in solid tumors.

How much funding did APVO raise in Q3 2024?

Aptevo raised $5.75 million through two financing rounds during the third quarter of 2024.